[ad_1]
By Davit Kirakosyan
10x Genomics, Inc. (NASDAQ:) shares dropped more than 12% after-hours following the company’s preliminary Q2 results, with revenue expected to be approximately $114.5 million (down 1% year-over-year), missing the Street estimate of $127.7 million.
“Our second quarter results fell short of our expectations,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We continue to have strong confidence in our longer-term opportunity, technology leadership and the underlying strength of our markets. We are more excited than ever to deliver on the full potential of single cell and spatial biology.”
Kijangwin is your brand-new go-to destination for all things internet gaming. Whether you're an informal…
Hey there, fashion enthusiasts! Are you ready to dive into the world of trendy clothes…
Hey there! If you're reading this, there's a good chance you've found yourself in the…
Hey there, hemp enthusiasts! If you've been on the hunt for the next big thing…
Hey there! Have you ever found yourself tangled up in the world of communication and…
Are you worried that hidden critters might derail your home sale? Selling a house can…